Table 1 Baseline demographics and laboratory characteristics of enrolled patients
Characteristics | n = 303 |
|---|---|
Gender, n (%) | |
Male | 293 (96.7) |
Female | 10 (3.3) |
Age, year | |
M (IQR) | 40 (34–49) |
Range | 22–85 |
Prior duration of ART, year | |
M (IQR) | 4.4 (2.7–7.3) |
Range | 0.5–15 |
Prior ART regimen, n (%) | |
Backbone agents | |
Tenofovir | 157 (51.8) |
Zidovudine | 80 (26.4) |
Abacavir | 47 (15.5) |
Tenofovir alafenamide | 19 (6.3) |
Core agents | |
INSTIs | 128 (42.2) |
NNRTIs | 150 (49.5) |
PIs | 25 (8.3) |
Reasons for switching, n (%) | |
Simplification | 152 (50.2) |
Antiretroviral-related toxicities | 142 (46.9) |
Dyslipidaemia | 77 (25.4) |
Renal toxicity | 28 (9.2) |
Central nervous system adverse events | 17 (5.6) |
Osteotoxicity | 10 (3.3) |
Liver toxicity | 6 (2.0) |
Lipoatrophy | 4 (1.3) |
Other | 9 (3.0) |
CD4 counts, cells/μL (n = 158) | |
M (IQR) | 514 (375–759) |
Range | 106–1213 |
CD4/CD8 ratio | |
M (IQR) | 0.64 (0.42–0.89) |
HIV-RNA, n (%) | |
< 50 copies/mL | 77 (25.4) |
Unknown at baseline | 226 (74.6) |
< 50 copies/mL within one year prior to ART switch | 177 (58.4) |
≥ 50 copies/mL within one year prior to ART switch | 5 (1.7) |